8-K: Clene Inc. Reports Positive Clinical Data and First Quarter 2024 Financial Results

Clene Inc. announced its first quarter 2024 financial results, highlighting positive clinical data from its CNM-Au8 program and a $7.3 million NIH sub-award.

Summary

• Clene Inc. released its first quarter 2024 financial results, reporting a net loss of $11.1 million, or $0.09 per share.
• The company's cash, cash equivalents, and marketable securities totaled $27.9 million as of March 31, 2024.
• Clene anticipates its current resources will fund operations into the fourth quarter of 2024.
• Research and development expenses decreased to $5.9 million, compared to $7.4 million in the same period last year.
• The company received a $7.3 million sub-award from an NIH grant for its ALS Expanded Access Program.
• Clinical data from the VISIONARY-MS trial showed significant evidence of repair and remyelination with CNM-Au8 treatment.
• More than half of the participants in the MS trial improved by 10 or more letters on a low-contrast eye chart, with some improving up to 38 letters.
• Participants in the MS trial also experienced up to 29 points of improvement in cognition and working memory.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical data and expected financial losses. The positive clinical trial results and NIH grant are encouraging, but the company's financial position and reliance on future funding temper the overall sentiment.

Positives

• The long-term extension of the VISIONARY-MS trial showed significant evidence of repair and remyelination with CNM-Au8 treatment.
• The company secured a $7.3 million sub-award from an NIH grant for its ALS Expanded Access Program.
• Clene's cash position is expected to fund operations into the fourth quarter of 2024.
• Research and development expenses decreased year-over-year, indicating cost management.

Negatives

• Clene reported a net loss of $11.1 million for the first quarter of 2024.
• The company's cash position decreased from $35.0 million at the end of 2023 to $27.9 million as of March 31, 2024.
• Total other expenses increased year-over-year, primarily due to changes in the fair value of common stock warrant liabilities.

Risks

• The company's ability to continue as a going concern depends on obtaining sufficient funding.
• Clinical trials of drug candidates may not demonstrate safety and efficacy to the satisfaction of regulatory authorities.
• Changes in government regulations could impact the need for the company's drug candidates.
• The company is substantially dependent on the successful commercialization of its drug candidates.
• The company has a limited operating history, which may make it difficult to evaluate its current business and predict its future performance.

Future Outlook

Clene anticipates a productive and collaborative FDA meeting by mid-2024 and is laying the groundwork towards filing a New Drug Application in the second half of the year. The company expects its current resources will fund operations into the fourth quarter of 2024.

Management Comments

• In the first quarter our team worked diligently to advance our FDA discussions in ALS while continuing to generate more data supporting the neurological benefits and mechanism of action of CNM-Au8, said Rob Etherington, President and CEO of Clene.
• We look forward to a productive and collaborative FDA meeting by mid-2024 and laying the groundwork towards filing of a New Drug Application in the second half of the year.
• Additionally, we are very pleased to see the recent data from our long-term extension of the VISIONARY-MS study.

Industry Context

Clene's focus on neurodegenerative diseases aligns with a growing need for effective treatments in this area. The positive clinical data for CNM-Au8 in MS could position the company as a key player in the market. The NIH grant for ALS also highlights the importance of addressing this disease.

Comparison to Industry Standards

• Clene's reported net loss of $11.1 million is typical for a clinical-stage biopharmaceutical company, as these companies often incur significant R&D expenses before generating revenue.
• The decrease in R&D expenses from $7.4 million to $5.9 million year-over-year suggests a shift in focus or cost management, which is common as companies progress through clinical trials.
• The positive clinical data from the VISIONARY-MS trial, showing significant improvements in vision and cognition, is a strong indicator of potential efficacy, which is a key metric for companies in this sector.
• Companies like Biogen and Novartis, which have established MS treatments, serve as benchmarks for Clene's clinical and commercial aspirations. Clene's results are promising but need to be validated in larger trials.
• The $7.3 million NIH sub-award is a positive sign of external validation and funding, which is crucial for biotech companies. This is comparable to other companies receiving government grants for specific research programs.

Stakeholder Impact

• Shareholders may view the positive clinical data and NIH grant as positive developments.
• Employees may be encouraged by the progress of the clinical programs and the company's financial outlook.
• Patients with neurodegenerative diseases may see hope in the potential of CNM-Au8.
• Creditors may be concerned about the company's net loss and cash burn rate.

Next Steps

• Clene plans to have a productive and collaborative FDA meeting by mid-2024.
• The company is working towards filing a New Drug Application in the second half of the year.
• Clene will continue to advance its clinical programs and generate more data supporting the neurological benefits of CNM-Au8.

Key Dates

Keywords

CNM-Au8, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Clinical Trial, Remylination, NIH Grant, Financial Results, Biopharmaceutical, Mitochondrial Health